Vaxxas

Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis.

Recent inflection

What moved lately